DNTH stock

Dianthus Therapeutics Inc. (DNTH) support and resistance · rev $6.2M

Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.

This page maps Dianthus Therapeutics Inc. (DNTH) support and resistance from cached range and valuation — not a live tape and not a trade alert.

Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.

DNTH currently screens at market cap $4.40B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.

A new DNTH 8-K or 10-Q can move the levels that matter more than a drawing on a chart.

Not investment advice. Use the DNTH quote page for the session range and the stock page for the full model.

Not investment advice.

Full DNTH analysis